Clinical Trial Update: Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Vebreltinib in combination with chemotherapy as first-line treatment for MET-overexpressing non-small cell lung cancer; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vebreltinib (vebreltinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING